Focused On-demand Library for Dual specificity tyrosine-phosphorylation-regulated kinase 1A

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q13627

UPID:

DYR1A_HUMAN

Alternative names:

Dual specificity YAK1-related kinase; HP86; Protein kinase minibrain homolog

Alternative UPACC:

Q13627; O60769; Q92582; Q92810; Q9UNM5

Background:

Dual specificity tyrosine-phosphorylation-regulated kinase 1A, also known as Dual specificity YAK1-related kinase, HP86, and Protein kinase minibrain homolog, is a multifunctional enzyme with both serine/threonine and tyrosine kinase activities. It plays a pivotal role in DNA damage repair, transcription regulation, cell proliferation, alternative splicing, and cell survival mechanisms.

Therapeutic significance:

This protein's involvement in Intellectual developmental disorder, autosomal dominant 7, underscores its potential as a therapeutic target. Understanding the role of Dual specificity tyrosine-phosphorylation-regulated kinase 1A could open doors to potential therapeutic strategies.